Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a note issued to investors on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

Shares of AXDX opened at $1.13 on Monday. The company has a market cap of $28.30 million, a P/E ratio of -0.40 and a beta of 0.55. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $2.09. The stock has a fifty day moving average price of $1.17 and a 200 day moving average price of $1.46.

Institutional Trading of Accelerate Diagnostics

Several large investors have recently added to or reduced their stakes in AXDX. Jane Street Group LLC acquired a new stake in Accelerate Diagnostics in the 4th quarter valued at approximately $27,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Accelerate Diagnostics during the third quarter valued at approximately $34,000. Renaissance Technologies LLC increased its stake in shares of Accelerate Diagnostics by 160.6% during the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock valued at $128,000 after acquiring an additional 65,984 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Accelerate Diagnostics by 6.9% during the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 8,777 shares during the period. 17.14% of the stock is currently owned by institutional investors and hedge funds.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.